A real-world study of the clinical efficacy of Zilongjin tablets in patients with non-small cell lung cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400085550

Enrollment

Unknown

Registered

2024-06-12

Start date

2024-06-20

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

exposure group (Take Zilongjin tablets for treatment):none

non-exposure group (Do not take Zilongjin tablets):none

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) histologically or cytologically confirmed patients with non-small cell lung cancer; 2) Age>18; 3) patients with good compliance; 4) expected survival =3 months; 5) agreed to participate in this study and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1) pregnant or lactating women; 2) patients with mental illness

Design outcomes

Primary

Measure	Time frame
Survival rate;Overall survival;Median survival;	—

Secondary

Measure	Time frame
Tumor size;Evaluation of the efficacy of antitumor therapy;Quality of life;Patient's physical activity status;	—

Countries

China

Contacts

Public ContactWang Xiaomin

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

ntxm100@sina.com+86 130 5127 2736

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026